Gilgamesh Pharmaceuticals, Inc. Total raised
$51 M
3 rounds on record
Latest round
$14 M
May 2022
First round on record
Apr 2020
Today
Acquired
Acquired by AbbVie Inc.
Acquired Matched to this startup by its exact name; the buyer's report is the source.
Funding rounds 3 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Gilgamesh Pharmaceuticals, Inc. Month Raised Raise Size Investors Sold Filing May 2022 $14 M No. 3 $10 to $50 million 14
Gilgamesh Pharmaceuticals, Inc.: Raise no. 3, May 2022 × Investors in this round 14 investors had bought by the notice of May 19, 2022: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Gilgamesh Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $50 M offered; $36 M still to sell
Smallest investment taken $50,000
What was sold equity, other: Shares of preferred stock of Issuer (Preferred Shares), and the shares of capital stock of the Issuer into which the Preferred Shares may convert. Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Kruegel · Executive Officer, Director Gerard Marek · Executive Officer Jonathan Sporn · Executive Officer, Director Laszlo Kiss · Executive Officer Thomas Kevin Murphy · Executive Officer Yoni Falkson · Executive Officer Amy Kruse · Director Gaetano Kevin Crupi · Director Phil Skolnick · Director Robert Berman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Some of the proceeds will be used to pay the salaries of the officers of the Issuer in the ordinary course of business.”Signed by John Fallone, Attorney for Issuer. Newest notice filed May 19, 2022. Read the notice at the SEC .
equity SEC Apr 2021 $35 M No. 2 $10 to $50 million 66
Gilgamesh Pharmaceuticals, Inc.: Raise no. 2, Apr 2021 × Investors in this round 66 investors had bought by the notice of May 6, 2021: 66 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Gilgamesh Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $35 M of $35 M offered
Smallest investment taken $10,000
What was sold equity, other: In addition to the shares of preferred stock sold by the Issuer, the shares of Issuer capital stock into which such shares of preferred stock may convert. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $630,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Kruegel · Executive Officer, Director Jonathan Sporn · Executive Officer, Director Amy Kruse · Director · Kruse was appointed as a Director, effective upon closing of the transaction. Dalibor Sames · Director · Sames resigned as a Director, effective upon closing of the transaction. Robert Berman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Some of the proceeds will be used to pay the salary of executive officers of the Issuer.”Signed by John Fallone, Attorney for Issuer. Newest notice filed May 6, 2021. Read the notice at the SEC .
equity SEC Apr 2020 $2 M No. 1 $2 to $10 million 25
Gilgamesh Pharmaceuticals, Inc.: Raise no. 1, Apr 2020 × Investors in this round 25 investors had bought by the notice of Jul 10, 2020: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Gilgamesh Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Kruegel, Ph.D. · Executive Officer Jonathan Sporn, M.D. · Executive Officer, Director · President and Chief Executive Officer Thomas Kevin Murphy, Ph.D. · Executive Officer Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jonathan Sporn, M.D., President and Chief Executive Officer. Newest notice filed Jul 10, 2020. Read the notice at the SEC .
equity, debt SEC
What its filings and its own website say, sentence by sentence, each with its source.
Gilgamesh Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2022).
SEC Form D · May 2022
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2022
In its own words How the company describes itself to search engines on its website, word for word.
“A clinical-stage neuroscience biotech developing innovative new chemical entities that transform the treatment paradigm of psychiatric disease.” As of Nov 15, 2026
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
1 named in official filings. Open an investor to see everything it has backed.
Investors in Gilgamesh Pharmaceuticals, Inc. Investor Kind Amount Round Role Source Ayuh Ventures Venture capital not stated not stated Investor Wikidata
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Gilgamesh Pharmaceuticals, Inc. Name Role Named in Andrew Kruegel Executive officer May 2022 Gerard Marek Executive officer May 2022 Jonathan Sporn Executive officer May 2022 Laszlo Kiss Executive officer May 2022 Thomas Kevin Murphy Executive officer May 2022 Yoni Falkson Executive officer May 2022 Andrew Kruegel, Ph.D. Executive officer Jul 2020 Jonathan Sporn, M.D. President and Chief Executive Officer Jul 2020 Thomas Kevin Murphy, Ph.D. Executive officer Jul 2020 Amy Kruse Director May 2022 Andrew Kruegel Director May 2022 Gaetano Kevin Crupi Director May 2022 Jonathan Sporn Director May 2022 Phil Skolnick Director May 2022 Robert Berman Director May 2022 Dalibor Sames Sames resigned as a Director, effective upon closing of the transaction. May 2021 Jonathan Sporn, M.D. President and Chief Executive Officer Jul 2020
American clinical-stage neuroscience biotechnology company.
Acquired (Jan 1, 2025). Acquired by AbbVie Inc..